Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.3 million.

  • Seres Therapeutics' Net Cash Flow rose 15124.77% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 7989.15%. This contributed to the annual value of -$96.7 million for FY2024, which is 17572.36% down from last year.
  • Seres Therapeutics' Net Cash Flow amounted to $2.3 million in Q3 2025, which was up 15124.77% from -$13.5 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Net Cash Flow ranged from a high of $153.5 million in Q3 2021 and a low of -$68.2 million during Q1 2023
  • Over the past 5 years, Seres Therapeutics' median Net Cash Flow value was -$26.4 million (recorded in 2022), while the average stood at -$3.1 million.
  • As far as peak fluctuations go, Seres Therapeutics' Net Cash Flow plummeted by 45545.97% in 2022, and later soared by 61076.3% in 2023.
  • Over the past 5 years, Seres Therapeutics' Net Cash Flow (Quarter) stood at -$39.5 million in 2021, then dropped by 7.38% to -$42.4 million in 2022, then grew by 1.0% to -$41.9 million in 2023, then increased by 11.23% to -$37.2 million in 2024, then skyrocketed by 106.07% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, -$13.5 million for Q2 2025, and $28.1 million during Q1 2025.